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Abstract: 
Background: Antimalaria combination therapy with regimen containing an artemisinin-based compound has been 
recommended as a gold standard and first-line treatment for malaria by WHO. Studies have also proven the 
effectiveness of Artemisinin-based Combination Therapy (ACT) in the treatment of uncomplicated Plasmoduim 
falciparum and delaying the emergence of drug resistance. However, limited reports exist on the effects of ACT on 
some vital biochemical parameters such as glucose-6-phosphate dehydrogenase (G6PD) and blood glucose 
concentration. This study therefore investigates and compares the effects of Artesunate-Amodiaquine combination 
therapy and Amodiaquine monotherapy on G6PD activity, fasting blood glucose level and parasite clearance rate in 
malaria-infected adults in Abakaliki, Nigeria. Methodology: Twenty adults aged between 20 and 30 years were used 
for the study. The patients were divided into two groups-A and B of 10 individuals each. Group A was given 
Artesunate-Amodiaquine (AS-AQ) while group B was given Amodiaquine (AQ). Blood samples were collected from 
each individual at baseline (Day 0) and after drug treatment (Day 4) for the comparative analysis of G6PD activity, 
fasting blood glucose level and parasite clearance rate. Result: There was an increase in G6PD activity after drug 
treatment in the two groups but the increase was not statistically significant. Glucose levels decreased after treatment 
in both groups but the decrease was also insignificant. There was a significant (P<0.001) difference in malaria 
parasite density of both groups after drug administration. The percentage parasite clearance of AS-AQ treated group 
and the AQ treated group were 67% and 47% respectively. Conclusion: There were no significant differences in the 
AS-AQ and AQ effects on the G6PD activity and fasting glucose level. In contrast, AS-AQ therapy indicated higher 
parasitic clearance rate compared to the AQ therapy. This further proves that Artemisinin-based Combination 
Therapy (ACT) is more effective than monotherapy in the treatment of malaria. 
Keywords: Artemisinin- Amodiaquine, Combination therapy, Amodiaquine, Parasite clearance, G6pd, Glucose. 
 
1.Introduction 
Malaria affects half of the world’s population and is the third leading cause of death for children under five years 
worldwide (WHO, 2011). Nigeria is one of the countries most affected by malaria and accounts for 25 per cent of 
global malaria cases. It is estimated that about 97% of Nigeria’s population are at risk of malaria. According to data 
from Carter Centre for Malaria Control Programme, over 300,000 Nigerians—mostly children—die from malaria 
attack each year (WHO, 2011). 
Of major concern are several reports of increasing incidence of multi-drug resistant Plasmodium falciparum malaria, 
which is responsible for the increasing cases of malaria in this region (Olurishe et al, 2007; Roll Back Malaria 
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Partnership Secretariat, 2010). In an attempt to reduce the incidence of relapse and treatment failure due to large 
scale resistance to existing drugs, the World Health Organization has advocated the use of Artemisinin-based 
combination therapy (ACT) for the treatment of malaria (Olurishe et al, 2007). ACTs are preferred because 
artemisinin compounds have rapid parasite and fever clearance effects and reduce gametocyte rate with the potential 
to reduce transmission (Meremikwu et al, 2006). Studies (White, 1999; Meremikwu et al, 2006; Meremikwu et al, 
2012; Marli et al, 2013; Mathieu et al, 2013; Stephan, 2013) have also proven the effectiveness of ACTs in the 
treatment of uncomplicated Plasmoduim falciparum and delaying the emergence of drug resistance. However, the 
lack of alternative drugs to artemisinin derivatives (Dondorp, 2009; Dondorp, 2010; Phyo, 2012) and their short 
half-lives and susceptibility to recrudescence, when given as monotherapy (Ashton et al, 1998) are the major 
drawbacks of the artemisinin derivatives. Using ACT in areas co-endemic for P. falciparum and P. vivax has been 
suggested as a strategy to overcome difficulties in differential diagnosis and in cases of mixed infection (Douglas, 
2010). 
All artemisia species seem to have hypoglycemic effect. Treatment of rats with Artemisia annua aqueous extract 
reduced the serum glucose after 4 weeks from 110 to 70 mg/dl (Mojarad, 2005). In South Africa Artemisia afra is 
extensively used for several diseases including diabetes. Methanol extracts of A. absinthium have a strong 
hypoglycemic and hepatoprotective activity (Goud, 2011). For A. herba alba the ethanol-water extract produced 
stronger hypoglycemic effect than the hexane extract (Awad, 2012). A. sieberi has been studied for a similar effect in 
Iran. Artemisinin and its combination with amodiaquine resulted in lowered plasma glucose hence an index of 
suspicion should be put on possibility of hypoglycaemia with the use of ACTs (Olayemi et al, 2012).  
There is paucity of reports on the effects of ACT on some vital biochemical parameters such as G6PD and blood 
glucose concentration. Few studies, which demonstrated the hypoglycemic effects of ACT, were conducted on 
animals (rats and mice). It is true that these animals are considered comparable genetic models to humans; however, 
they exhibit natural differences in susceptibility to malarial infection. The present study therefore investigated the 
effects of Artesunate-Amodiaquine combination therapy on G6PD activity, fasting glucose level in comparison with 
the effects Amodiaquine monotherapy on these biochemical parameters in adult humans. In addition, we also 
demonstrated if there is significant difference in the rate of parasite clearance in blood between patients treated with 
Amodiaquine and those treated with Artesunate-Amodiaquine (AS-AQ). 
 
2. Research Design and Methods 
2.1 Subjects 
Twenty adult individuals within the ages of 20-30 years (mean age of 25years) with uncomplicated P. falciparum 
malaria were used for the study. They were divided into two groups (A and B) comprising ten individuals in each 
group. Individuals with any form of G6PD deficiency (G6PD value of <6 μ/gHb), diabetics and pregnant women 
were excluded from the study. The subjects’ consents were obtained before participation and they were assured of 
their safety and privacy throughout the study. Participation was voluntary and withdrawal from the study at anytime 
was allowed.  
2.2 Drug treatment  
Before treatment was given, blood sample from each individual from the groups was collected for the determination 
of parasite density (parasiteamia), fasting blood glucose and G6PD enzyme activity at baseline.  
Artemisinin-based Combination Therapy (ACT) - Artesunate-Amodiaquine (AS-AQ) supplied as Camosunate 
(Adams Pharmaceutical (ANHUI) co.ltd Xuancheng Economic and Technical Development Zone ANHUI, China 
email; export@adamspharm.com). Adult (14 years and above) formulation is Amodiaquine base-300mg 
+Artesunate-100mg (12 tablets per sachet).  Group A was given Artesunate-100mg (2 white tablets) one for 
morning, one for evening daily for three days together with Amodiaquine-300mg (2 yellow tablets) one for morning, 
one for evening daily for three days. 
Amdaquine supplied as Camoquin (Pfizer Afrique de I’Quest-B.P 3857 Dakar R.P-Senegal). Dosage: Group B was 
given Amodiaquine-600mg one daily for three days (200mg per tablet x 3= 600mg). 
2.3 Blood sample collection  
Before the commencement of treatment (Day 0), blood samples were collected from subjects in each group for the 
determination of parasite density (parasiteamia), fasting blood glucose and G6PD enzyme activity at baseline. The 
drug treatment commenced on (Day 1) and lasted for three days. On (Day 4) another blood sample was collected 
from each individual in the two groups for the analysis of G6PD activity, fasting glucose level and parasite clearance 
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rate. About 10ml of blood was collected from each individual (before and after treatment) and shared into EDTA 
(ethylene di-aminotetra acetic acid) and K-O,NaF (potassium oxalate, sodium fluoride) bottles. Sample in the EDTA 
bottle was used for the analysis of G6PD enzyme activity and Parasite density while the sample in K-O Na-F bottle 
was used for the analysis of fasting blood glucose level. 
2.4 Laboratory procedures 
G6PD enzyme activity was determined using spectrophotometric method of Horecker and Komberg, (Randox 
Laboratories Ltd United Kingdom). Normal range of G6PD activity in erythrocyte as prescribed by Randox G6PD 
Kit (2010) is 6.97- 20.5 U/gHb. Baseline values outside this range were excluded.  Fasting blood glucose level was 
measured using glucose oxidase method by Randox Laboratories Ltd United Kingdom 2010. Normal fasting blood 
glucose for adult is 60-110mg/dl. Parasitaemia assessment was done using a thick film stained with giemsa. A 
minimum of 200 WBC were counted per slide of a sample. Malaria parasite density was determined by dividing the 
number of parasites counted by the number of WBCs x 8000/1 = parasites/ml of blood. Blood films were considered 
negative if no parasites were seen in 100 oil-immersion fields in a thick blood film.  
2.5 Statistical analysis 
Data was expressed as mean and standard deviation. Comparative analysis involving two continuous variables was 
done using independent sample t-test. Experimental data were analysed using analysis of variance (ANOVA). A post 
Hoc comparison (Bonferonni) test was performed to further ascertain significant differences between means. 
Statistical significance was set at P<0.05. All statistics were done using SPSS for Windows (version 16.0). 
 
3. Results  
Data indicated that there were no significant differences in G6PD activity, fasting glucose level and malaria parasite 
density between patients in the groups at baseline (Table 1). 
No significant differences were observed in G6PD activity and fasting glucose level of both groups after treatment. 
On the contrary, significant (P<0.01) difference was observed in malaria density between patients treated with 
amodiaquine and those treated with artesunate/amodiaquine. Data indicated that parasite density was significantly 
reduced in patients treated with artesunate/amodiaquine compared to those treated with amodiaquine (Table 2).  
The activity of G6PD enzyme was found to be increased after amodiaquine treatment but the increase was not 
significant. On the other hand, fasting blood glucose level was found to decrease but the decrease was insignificant. 
Significant (P<0.001) decrease was observed in malaria density after treatment with amodiaquine. Data indicated 
that there was a significant reduction in parasite density after treatment with amodiaquine compared to the value 
before treatment (Table 3). 
No significant difference was observed in G6PD activity after treatment with artesunate/amodiaquine. There was a 
decrease in fasting glucose level after artesunate/amodiaquine treatment but the decrease was insignificant (P>0.05). 
On the contrary there was significant (P<0.001) reduction in the malaria parasite density after treatment with 
artesunate/amodiaquine (Table 4).  
Data indicated that patients treated with artesunate/amodiaquine had significantly (P = 0.004) higher percentage 
(67.49%) clearance of malaria parasites compared to those treated with amodiaquine (47.76%). This shows that 
artesunate/amodiaquine (artemisinin-base combination therapy) has higher efficacy than does Amodiaquine 
monotherapy (Table 5). 
 
4. Discussion 
The spread of multidrug-resistant Plasmodium falciparum malaria throughout the world has led WHO to recommend 
combination therapy as first-line treatment, with regimens containing an artemisinin based compound as a gold 
standard. The goal of Artemisinin-based Combination Therapy (ACT) is to enhance cure rates while simultaneously 
delaying the development of resistance to component drugs (White, 1999). The present study indicated that after 3 
days of treatment, patients administered with artesunate/amodiaquine had significantly higher parasitaemia clearance 
of 67.49% compared to those treated with amodiaquine monotherapy who had a clearance rate of 47.76% and with 
no adverse effects recorded. In addition, there was lack of significant differences in fasting blood glucose level as 
well as G6PD activities between patients treated with artesunate/amodiaquine combination therapy and those treated 
with amodiaquine monotherapy. 
The higher parasitemia clearance observed in the artesunate/amodiaquine combination therapy relative to 
amodiaquine monotherapy in the present study suggests that ACT has higher efficacy over monotherapy. Our finding 
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agrees with some studies which have shown that Artemisinin-based combination therapy has indeed proven to be 
more effective compared to the initial monotherapy (Meremikwu et al, 2006; Abdoulaye et al, 2010; Stephan et al, 
2013). The use of artemisinin-based combination therapy (ACT) is previously associated with a rapid clearance of 
the parasite and a low probability of drug-resistant parasite emergence (White, 1999). ACT has also been shown to 
cure malaria in mice at very low dosages (Marli et al, 2013). The AS-AQ parasitemia clearance rate (67%) observed 
in the present study was lower than that observed in a study in Congo, which showed high efficacy of 94% (Mathieu 
et al, 2013). The assessment of artesunate/amodiaquine combination therapy by Meremikwu et al (2012) showed a 
therapeutic efficacy rate of 82.5% (Meremikwu et al, 2006; Meremikwu et al, 2012). However, these studies had 
longer treatment days (28 days) compared to the present study. The present finding therefore is an indication of high 
therapeutic efficacy of AS-AQ compared to Amodiaquine monotherapy in the treatment of malaria infection. 
The pharmacological hallmark of the artemisinin derivatives is that they clear parasitaemia more rapidly than other 
drugs (White, 2011), however, not much is known about the adverse effect (if any) this ACT might have on some 
vital biochemical parameters. The present data indicated that there was insignificant decrease in fasting blood 
glucose level in both groups treated with artesunate-amodiaquine and amodiaquine monotherapy after the third day. 
The present finding is suggestive of slight hypoglyceamic effect of both antimalarial drugs. However, previous 
studies have reported significant reductions in glucose levels after artemisinin based therapy. For example, treatment 
of rats with Artemisia annua aqueous extract significantly reduced the serum glucose from 110 to 70 mg/dl after 4 
weeks (Mojarad, 2005). Artemisia afra, Artemisia absinthium, Artemisia sieberi and Artemisia herba alba have also 
been shown to have hypoglyceamic effects (Awad, 2012). This shows that the hypoglycaemic activity of ACT 
anti-malarial is deposited in the Artemisinin group derived from artemisia. Treatment with artesunate, amodiaquine, 
artesunate-amodiaquine combination and quinine on mice infected with plasmodium berghei also indicated 
significantly lower plasma glucose compared to the control group, thus suggesting the possibility of hypoglycaemia 
with the use of ACTs (Olayemi et al, 2012). It is of noteworthy that the slight decrease (though not significant) in 
blood glucose observed in both ACT and amodiaquine treated patients is an indication that both drugs may exhibit 
hypoglycaemic effect. However, no literature supports the glucose lowering ability of amodiaquine or its 
derivative-quinoline. We recommend further studies to establish the hypoglyceamic effect of ACT and Amodiaquine 
monotherapy by extending the study to longer days. 
The glucose VI phosphate dehydrogenase is an enzyme that protects the red cells from oxidative injury caused by 
oxidants and drugs (Luzzatto et al, 2001; Beutler et al, 2002; Abdoulaye et al, 2010). Our data indicated lack of 
significant differences in G6PD activities before and after treatment with both drug regimens. This indicates lack of 
adverse/hemolytic effects of both drug regimens on red blood cells and consequently related hematological indices in 
G6PD normal/sufficient individuals. To the best of our knowledge, there is lack of scientific literatures on the effects 
of ACTs and monotherapies on G6PD activities in G6PD sufficient individuals treated for malaria infection. The 
present findings therefore call for further research to confirm our findings and elucidate more facts on this subject 
matter. 
 
5. Conclusion 
There were no significant differences in the G6PD activity and fasting blood glucose after artesunate-amodiaquine 
and amodiaquine monotherapy treatments. In contrast, AS-AQ therapy indicated higher parasitic clearance rate 
compared to the AQ therapy. This further proves that Artemisinin-based Combination Therapy (ACT) is more 
effective than monotherapy in the treatment of malaria. Further studies on hypoglyceamic effect of ACT and 
Amodiaquine monotherapy and the effects of ACTs and monotherapies on G6PD activities in G6PD sufficient 
individuals treated for malaria infection are needed and the research should be extended to 28 days or more. 
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Table 1. Baseline mean values of G6PD enzyme activity, fasting blood glucose level and malaria parasite density in 
subjects before treatment with anti-malaria drugs. 
VARIABLES AMODIAQUINE 
Baseline 
GROUP B 
ARTES/AMODIAQUINEBaseline 
 GROUP A 
t-STAT P 
G6PD(μ/gHb) 
 
Glucose(mg/dl) 
 
Parasite Density(count/ml) 
8.9 ± 1.52 
 
77.40 ± 21.52 
 
5906.2 ± 852.23 
9.06 ± 1.67 
 
77.0 ± 16.73 
 
5322.6 ± 1103.32 
-0.15 
 
0.04 
 
1.30 
0.88 
 
0.97 
 
0.23 
Table 2. G6PD activity, fasting glucose level and malaria parasite density in subjects after treatment with 
anti-malaria drugs. 
VARIABLES AMODIAQUINE 
TREATED 
GROUP B 
ARTES/AMODIAQUINE 
TREATED 
 GROUP A 
t-STAT P 
G6PD(μ/gHb) 
 
Glucose (mg/dl) 
 
MALARIA 
DENSITY(count/ml) 
9.1 ± 1.66 
 
70.8 ± 14.57 
 
 
3086.1±739.26 
9.2 ± 1.74 
 
72.6 ± 14.96 
 
 
1720.8±553.09 
-0.10 
 
-0.28 
 
 
4.16 
0.92 
 
0.78 
 
 
0.002 
Table 3. G6PD activity, fasting glucose level and malaria parasite density before and after treatment in subjects 
treated with amodiaquine 
VARIABLES BEFORE TREATMENT AFTER TREATMENT t-STAT P 
G6PD(μ/gHb) 
 
Glucose (mg/dl) 
 
Parasite Density(count/ml) 
8.94 ± 1.52 
 
77.4 ± 21.52 
 
5906.2 ± 852.23 
9.1 ± 1.66 
 
70.8 ± 14.57 
 
3086.1 ± 739.27 
-0.19 
 
0.80 
 
7.90 
0.85 
 
0.43 
 
0.000 
Table 4. G6PD activity, fasting glucose level and malaria parasite density before and after treatment in subjects 
treated with artesunate/amodiaquine drug. 
VARIABLES BEFORE TREATMENT AFTER TREATMENT t-STAT P 
G6PD(μ/gHb) 
 
Glucose (mg/dl) 
 
Parasite Density(count/ml) 
9.1 ± 1.67 
 
77.0 ± 16.73 
 
5322.6 ± 1103.3 
9.2 ± 1.74 
 
72.6 ± 14.96 
 
1720.8 ± 553.09 
-0.14 
 
0.62 
 
9.23 
0.89 
 
0.54 
 
0.000 
Table 5. The percentage malaria parasite clearance in patients treated with amodiaquine and artesunate/amodiaquine 
drugs. 
DRUGS BEFORE 
TREATMENT 
AFTER 
TREATMENT 
DIFFERENCE % CLEARANCE 
Amodiaquine 
 
Artes/Amodquine 
5906.2± 852.23 
 
5322.6± 1103.3 
3086.1±739.27 
 
1720.8± 553.09 
2820.1± 778.92 
 
3601.8± 936.18 
47.76 ± 10.62 
 
67.49 ± 7.96 
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